Dear Editor, I was interested to read the case report by Spinedi et al. 1 of successful lysis of a stroke following endovenous laser ablation. My attention was particularly drawn to the decision to give, and the duration of administration of, prophylactic low-molecular weight heparin (LMWH) during the perioperative period.
LMWH is now the recognised mainstay of pharmacological thromboprophylaxis, delivering reductions in post-operative DVT in general surgical patients in the order of 76% when compared to placebo. 2 Unfortunately, management of thromboprophylaxis in patients undergoing endovenous treatment is highly variable. Complete absence of level-one evidence or specific guideline recommendations has led some practitioners to question the need for pharmacological thromboprophylaxis after ambulatory endovenous procedures. This lack of evidence is partly due to the fact that there is great difficulty in conducting high-quality research to guide practice. The relatively rare incidence of VTE in this patient group means that a randomised controlled trial would need such large numbers as to make it impractical.
However, cases such as that reported by Spinedi et al. (and recent high profile deaths from pulmonary embolism in the UK) indicate that there is a definite role for LMWH anti-DVT prophylaxis after ambulatory endovenous treatment in selected patients.
Patients should be selected for LMWH thromboprophylaxis by stratifying for individual venous thromboembolism (VTE) risk. Procedure-based stratifications based on surgery 'type' or 'time' are not useful for endovenous interventions as these are relatively minor procedures that usually last less than 60 min, although this case lasted 90 min thus warranting effective DVT prophylaxis. Patient-based risk assessment models such as the Caprini score 2 and the UK Department of Health VTE tool allow patient-specific risk stratification. Unfortunately, other than sex and race, we are given no information on the reported patient's potential risk factors such as the presence or otherwise of obesity, hormonal therapy, active thrombophlebitis, personal or family history of venous thromboembolism, reduced limb mobility and thrombophilia. We do not even know whether the procedure was ambulatory or performed under general anaesthesia.
Duration of prophylaxis, once a patient has been selected for LMWH treatment, is the second important area of concern. Whilst a majority of endovenous surgeons favour a single dose of LMWH thromboprophylaxis, as was used in this case, this strategy is not supported by haematologists. Evidence such as that from Sweetland et al. 3 demonstrate that day case surgery, including vascular cases, significantly increase DVT risk. This risk rises quickly on the day of surgery and remains elevated for several weeks into the postoperative period. In fact, the relative risk of DVT within six weeks of day-surgery is approximately 10 times higher than in patients without surgery. 3 Thus, giving a single shot of Enoxaparin (half-life -4.5 h) in theatre to patients with increased risk for DVT offers no protection beyond the first few hours of the ongoing risk high period.
There is an urgent need for a risk stratification model that focuses on risk factors directly relevant to varicose vein patients, to select patients for additional pharmacological VTE prophylaxis. Duration of post-intervention DVT risk is longer than currently recognised by endovenous practitioners and patients determined to be at increased risk for DVT should be given extended LMWH, and a minimum of one week has been suggested. 4 This should probably be extended to four to six weeks in very high-risk patients such as those with previous DVT or known thrombophilia. The current practice of 'one-shot' LMWH prophylaxis is ineffective, medicolegally indefensible and should be abandoned.
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